Key facts
- It has raised $620K.
- Notable investors include Techstars, Creative Destruction Lab, University of Toronto, gener8tor, Berkeley SkyDeck — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Gisens Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Gisens Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gisens Biotech
Developer of a nanotechnology-based device designed to diagnose and detect renal biomarkers. The company's platform leverages nanotechnology to develop a device that diagnoses and detects renal biomarkers, enabling scientists with real-time and portable health monitoring to measure urea, creatinine, and potassium levels from a single blood drop and track these metrics via an application.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2020
- Employees
- 14
- Website
- gisensbiotech.com/
- Ownership
- Privately Held (backing)
Gisens Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gisens Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gisens Biotech in its N-PORT filings yet. We sweep new filings monthly.